Tenax Therapeutics (TENX)
(Delayed Data from NSDQ)
$3.48 USD
-0.12 (-3.33%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $3.48 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Tenax Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 8 | 11 | 33 | 10 | 9 |
Income After Depreciation & Amortization | -8 | -11 | -33 | -10 | -9 |
Non-Operating Income | 1 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -8 | -11 | -32 | -10 | -8 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -8 | -11 | -32 | -10 | -8 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -8 | -11 | -32 | -10 | -8 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -8 | -11 | -33 | -10 | -8 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -8 | -11 | -33 | -10 | -9 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.25 | NA | 0.01 | 0.01 | 0.00 |
Diluted EPS Before Non-Recurring Items | -31.04 | NA | -2,528.00 | -2,128.00 | -2,160.00 |
Diluted Net EPS (GAAP) | -31.04 | -600.80 | -2,528.00 | -1,520.00 | -2,160.00 |
Fiscal Year end for Tenax Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.34 | 2.12 | 1.24 | 1.54 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.34 | -2.12 | -1.24 | -1.54 |
Non-Operating Income | NA | 0.41 | 0.15 | 0.14 | 0.14 |
Interest Expense | NA | 0.00 | 0.01 | 0.01 | 0.01 |
Pretax Income | NA | -3.23 | -1.97 | -1.11 | -1.41 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -3.23 | -1.97 | -1.11 | -1.41 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -3.23 | -1.97 | -1.11 | -1.41 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 0.30 | 0.28 | 0.12 |
Diluted EPS Before Non-Recurring Items | NA | NA | -6.40 | -4.00 | -12.00 |
Diluted Net EPS (GAAP) | NA | -8.64 | -6.40 | -4.00 | -12.00 |